


If clinicians in primary care have seriously ill patients, whom they suspect to have influenza but it is not during the period of confirmed influenza circulating in the community, please seek specialist advice



For recommendations on the use of COVID-19 and influenza diagnostic tests when considering prescribing treatment in at-risk patients see <u>Table 1</u> in the UKHSA guidance document

For further information, please contact your Primary Care Pharmacist



Table 1: Selection of antivirals for severely immunosuppressed patients⁶

N.B. **Oseltamivir and zanamivir- c**ommence therapy within 48 hours (36 hours for zanamivir in children) of onset (or later at clinical discretion)

	Dominant circulating strain has a lower risk of	Dominant circulating strain has a higher risk of
	oseltamivir resistance, e.g. A(H3N2), influenza B *	oseltamivir resistance, e.g. A(H1N1) *
Uncomplicated influenza	oseltamivir PO (see dosing schedule above) and clinical follow up.	zanamivir INH (Diskhaler®) 10mg (2 inhalations) twice daily for 5 days (unlicensed in children <5yrs) OR if unable to take inhaled preparation use oseltamivir PO and clinical follow up.
Complicated influenza (Treatment mainly	1st line: oseltamivir PO/NG (see dosing schedule above) 2nd line: zanamivir INH 10mg (2 inhalations) twice daily	zanamivir INH 10mg (2 inhalations) twice daily for 5 days (unlicensed in children <5yrs) via the Diskhaler OR
(reaction in in hospital)	 for 5 days (unlicensed in children <5yrs) via the Diskhaler if: poor clinical response to oseltamivir evidence of gastrointestinal dysfunction** subtype testing confirms a strain with potential oseltamivir resistance, e.g. A(H1N1) pdm09 OR consider referring to hospital for further management with zanamivir IV if patients: Are unable to self-administer inhaler zanamivir (due to underlying respiratory disease or inability to use the Diskhaler) Have severe complicated illness such as multi-organ failure Note: treatment should be commenced as soon as possible and usually within 6 days. 	 consider referring to hospital for further management with zanamivir IV if patients: Are unable to self-administer inhaler zanamivir (due to underlying respiratory disease or inability to use the Diskhaler) Have severe complicated illness such as multi-organ failure Note: treatment should be commenced as soon as possible and usually within 6 days.

* = (also applicable if this is the strain known to be infecting patient; treatment however, should not be delayed while waiting for test results).

** = Examples of gastrointestinal dysfunction include known gastroparesis, clinical evidence of malabsorption, uncontrollable vomiting, and gastrointestinal bleeding.

Table 2: Recommended dosage of oseltamivir in patients with renal dysfunction (adults aged 13 or over)⁶

Creatinine Clearance (eGFR may be used if CrCl is not available)	Oseltamivir PO (Treatment – 5 days)
Moderate impairment (CrCl 31-60mL/min)	30mg BD
Severe impairment (CrCl 11-30mL/min)	30mg OD
Established renal failure (CrCl <10mL/min)	30mg ONCE based on expert opinion

NB: For further information and prescribing guidance (based on expert opinion) for haemodialysis see section 2.3.2 <u>here</u> There is NO dose adjustment for **inhaled** zanamivir in renal impairment³.

There is NO dose adjustment for oseltamivir and zanamivir in hepatic impairment ^{2,3}.

Table 3: Advice for use in pregnancy⁶

Antivirals are recommended for pregnant women due to the adverse clinical outcomes that have been observed for influenza infection in this group.

Oseltamivir	First line option for the vast majority of pregnant women with influenza. Discuss with patient regarding risks	
	and benefits	
Zanamivir	For pregnant women who meet additional criteria for zanamivir first line, further rapid diagnostics and	
	treatment should be discussed with a local infection specialist	

For use while breastfeeding:

- For Infants born full term and healthy, both oseltamivir and zanamivir are considered acceptable for use in breastfeeding mothers. If the mother is receiving oseltamivir or zanamivir and the breastfed infant also needs direct treatment or prophylaxis, the recommended dose of oseltamivir or zanamivir for infants should be given to the infant.
- If an infant is unwell, premature, or the mother is taking multiple medicines, then an individual risk assessment will need to be made.

References

- 1. NICE technology appraisal guidance 168 Amantadine, oseltamivir and zanamivir for the treatment of influenza (Feb 2009). Click here
- 2. Summary of Product Characteristic Tamiflu® (Oseltamivir); accessed 2/12/21. Click here
- 3. Summary of Product Characteristics Relenza® (Zanamivir); accessed 2/12/21. Click here
- 4. Summary of Product Characetristics Dectova® (IV Zanamivir); accessed 2/12/21. Click here
- 5. BNFC online; accessed 2/12/21. Click here
- 6. UKHSA guidance on use of antiviral agents for the treatment and prevention of seasonal influenza November 2021. Click here
- 7. SPS medicines Q&A Oseltamivir or zanamivir Can mothers breastfeed after treatment for influenza? accessed 2/12/21 Click here